6FN.F KLARIA PHARMA HOLDING AB

Healthcare Pharmaceuticals Frankfurt Exchange
0.0421 EUR
Close of Nov 11, 2026
0.0367 0.1185
Market cap
EUR 10.4M
P/E
-
P/B
4.18x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6FN.F undervalued?

Graham number

The Graham number of KLARIA PHARMA HOLDING AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KLARIA PHARMA HOLDING AB fundamental analysis

No fundamental analysis for KLARIA PHARMA HOLDING AB yet.

KLARIA PHARMA HOLDING AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KLARIA PHARMA HOLDING AB

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention o…

Full company profile